By Peter Loftus

Moderna shares rose 3.5% Thursday after an advisory committee voted to recommend the U.S. Food and Drug Administration approve the biotech's proposed new flu shot for people 50 and older.

The FDA had initially declined to consider Moderna's application for the shot's approval, but then agreed to review it after Moderna amended it. The advisory committee vote in favor of the vaccine isn't binding, but the FDA generally follows such recommendations. A decision is expected by early August.

Shares of Moderna, which is trying to expand beyond Covid-19 vaccines, closed at their highest level since September 2024. The stock is up 39% over the past six trading days.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

June 18, 2026 17:30 ET (21:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.